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Background: Nodular regenerative hyperplasia (NRH) has been recently recognized as an emergent cause of liver
disease in HIV-infected patients. NRH may cause non-cirrhotic portal hypertension with potentially severe
consequences such as refractory ascites, variceal bleeding and hypersplenism. Obliteration of the small intrahepatic
portal veins in association with prothrombotic disorders linked to HIV infection itself or anti-retroviral therapy seem
to be the causes of NRH and thus the term HIV-associated obliterative portopathy has been proposed.
Case Presentation: Here we describe a case of a HIV-infected patient with biopsy-proven NRH and listed for liver
transplantation (LT) because of refractory ascites and repeated upper gastrointestinal bleedings. A transjugular
intrahepatic portosystemic shunt was placed as a bridge to LT and did not improve liver function. However,
anticoagulant therapy with low-molecular-weight heparin (LMWH) was associated with rapid improvement in the
liver condition and allowed to avoid LT in this patient.
Conclusions: Thus, this case underscores the relation between thrombophilia and HIV-associated NRH and
emphasizes anticoagulant therapy as possible treatment.
Background
Nodular regenerative hyperplasia (NRH) is a diffuse
disorder of the liver characterized by nodular transfor-
mation of the hepatic parenchyma without fibrosis.
NRH causes intra-hepatic non-cirrhotic portal hyper-
tension (NCPH)[1]. Recently, several reports described
HIV-infected patients with symptomatic NCPH reveal-
ing NRH [1-13]. Typical histopathological features of
NRH include atrophic hepatocytes together with areas
of hypertrophyic plates arranged in multilayer around
the portal tract, producing nodules in the absence of
significant fibrosis. The small portal veins are obliter-
ated leading to an atrophy of the supplied acinus and
to a subsequent hypertrophy of the adjacent acinus.
Sinusoidal dilatation is secondary to an increased
blood flow. The sum of these events has recently be
described by Mallet et al. coining the term HIV-asso-
ciated obliterative portopathy (HIV-OP) [10]. The pre-
valence of NRH is not well established because
diagnosis is difficult on needle biopsies and patients
are usually asymptomatic at early stages. Although the
cause of NRH is not fully understood, it seems that
NRH is secondary to HIV-OP and associated with an
hypercoagulable state [10,14,15]. A number of diseases
have been associated with NRH, in particular haema-
tological disorders with thrombophilia including mye-
loproliferative or lymphoproliferative diseases [15,16]
which can be found in more than half the patients
presenting with NRH [14]. In addition, autoimmune
diseases (e.g. systemic lupus erythematosus, rheuma-
toid arthritis, celiac disease, etc) and immune-suppres-
sion have been associated with NRH. The
thrombophilia in HIV-OP is thought to be an
acquired protein S deficiency with lower protein S
levels and decreased activity [10].
Treatment for NRH would ideally include correction
of triggering factors to prevent disease extension. How-
ever, therapy of NRH is usually limited to the treatment
of complications of portal hypertension, i.e. beta-block-
ers, variceal ligation and/or portosystemic shunts (TIPS).
Moreover, liver transplantation (LT) has been performed
in cases with severe portal hypertension and/or liver
failure [17,18]. Interestingly a recent case series of LT in
HIV-infected patients with NRH described an overall
good outcome [9].
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developed severe intrahepatic non-cirrhotic portal
hypertension due to NRH with a decreased proteins S
level and recurrent variceal bleeding, refractory ascites
and cachexia despite TIPS placement. The patient was
listed for liver transplantation. While awaiting LT, antic-
oagulant therapy with low-molecular-weight heparin
(LMWH) allowed spectacular and sustained improve-
ment of the patient’s condition, which led to remove the
patient from the waiting list. To our knowledge this is
the first case of HIV-related NRH that was successfully
treated with anticoagulant treatment avoiding liver
transplantation.
Case Presentation
In August 2005 a 43-year old woman with known HIV
infection since 1998 presented in the emergency depart-
ment with post-prandial abdominal pain and important
weight loss (10 kg) over 4 months. HIV infection was
treated since 2000 with a HAART including didanosine,
lamivudine and abacavir. At admission her absolute
CD4 count was 279/mm
3 and HIV viremia 270,000
copies/ml. Diffuse lymphoadenopathy, splenomegaly and
ascites were observed associated with biochemical
abnormalities of the liver parameters: aspartate amino-
transferase (AST) and alanine aminotransferase (ALT)
were 1.5 times upper normal range, alkaline phosphatase
(AP) twice and gamma-glutamyltransferase (gGT) four
times above normal values. There was neither alcohol
intake nor toxic exposure; screening was negative for
viral hepatitis (HAV, HBV, HDV, HCV and HEV), CMV
and EBV, autoimmune hepatitis (antinuclear antibodies,
antiactin antibodies and total serum immunoglobulins),
Wilson’s disease, hemochromatosis and schistosomiasis.
A thoraco-abdominal CT scan showed mediastinal and
axillar lymphadenopathies, pulmonary nodules and a
heterogeneous liver parenchyma with signs of portal
hypertension (esophageal varices, ascites and splenome-
galy). A transjugular liver biopsy revealed a slightly
abnormal portal pressure gradient (8 mmHg wedge gra-
dient) and the histology described normal parenchymal
architecture with a minimal portal fibrosis and sinusoi-
dal infiltration of mainly T lymphocytes (CD3+). A lym-
phoproliferative disease was ruled out by flow cytometry
of peripheral blood lymphocytes, intranodal lymphocytes
(axillar lymphnode biopsy) and of liver infiltrating lym-
phocytes. At this point our hypothesis pointed towards
a miliary tuberculosis with lung and peritoneal involve-
ment. In the ascites fluid the polymorphonuclear count
was low (PMN, <250 cells/mm
3) as also the albumin (10
gr/l) and protein level (9 gr/l) with a serum-to-ascites
albumin gradient (SAAG) of 2.6 pointing towards portal
hypertension. However, the cultures of the ascites fluid
tested positive for M. tuberculosis and treatment was
started with rifampin, isoniazid (INH) and ethambutol
for six months and thereafter bitherapy with INH and
rifampin (based on the antibiogram) for additional seven
months. An upper gastrointestinal endoscopy evidenced
grade I esophageal varices. For the viral breakthrough of
HIV, HAART was changed to tenofovir, efavirenz, ataza-
navir and ritonavir. The patient was dismissed from the
hospital but presented seven, eight, ten and 12 months
later severe esophageal variceal bleedings treated with
endoscopic band ligation and slerotherapy and beta-
blockers (propanolol).
In September 2006 she was admitted again for bilat-
eral leg swelling and important ascites with very low
proteins (7 gr/l, serum albumin 30 gr/l, serum-to-ascites
albumin gradient SAAG of 2.3). Liver function tests
were still abnormal: AST and ALT 1.5 ULN, AP 2×
ULN, gGT 4× ULN and diminisched Factor V (50%). An
abdominal CT scan and MRI showed large volume
ascites, splenomegaly and portal-systemic collaterals.
The portal vein was patent. A second transjugular liver
biopsy revealed again minimal portal fibrosis without
significant inflammation. On the reticulin stain a typical
nodular rearrangement of the parenchyma with atrophic
periportal and regenerative centrolobular plates was
compatible with NRH (Figure 1). In addition, fibrous
material was occluding portal veins in several portal
tracts pointing towards HIV-associated obliterative
portopathy.
Hence, in the context of HIV infection, we suspected a
hypercoagulable state with micro-thrombosis in the dis-
tal portal veins causing NRH. A thrombophilia work-up
(lupus anticoagulant, anticardiolipin and anti-b2-glyco-
protein I antibodies, factor II G20210A mutation, factor
V Leiden mutation, anti-thrombin, protein C and
Figure 1 A liver biopsy performed in September 2006 shows in
the reticulin stain an altered architecture with enlarged
hepatocytes arranged in small nodules (×400).
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(37% normal > 55%). An anticoagulant treatment with
vitamin K antagonists (VKA, acenocoumarol) aiming at
an INR of 2.0-3.0 was introduced. However, the anticoa-
gulant treatment with VKA was difficult to regulate
with highly variable INR, which was repeatedly infra-
therapeutic. In November 2006 she presented another
variceal bleeding (with an INR at 1.7) controlled by
band ligation, ascites and progressive cachexia (BMI
15.6). HIV infection was again uncontrolled and treat-
ment was changed to tenofovir, emtricitabin, lopinavir
and ritonavir. Thus, in February 2007 the patient was
listed for LT with a MELD score of 14. To bridge until
LT a TIPS was placed. Four weeks after the TIPS place-
ment, the anticoagulant treatment with VKA was still
extremely difficult to manage with unsatisfactory INR
levels. Low platelets counts, factor V level, and fibrino-
gen (2.1 g/l) together with high D-dimers were sugges-
tive of a persistent consumption coagulopathy and an
ongoing thrombotic process. For these reasons, anticoa-
gulant treatment was switched to LMWH in March
2007 for the next two months. With this treatment, the
factor V levels increased, D-dimers normalized and fibri-
nogen increased (to 6.5 g/l); this was all highly sugges-
tive of efficient anticoagulant treatment (resumed in
Figure 2). In May 2007 anticoagulant treatment was
switched back to VKA and INR could be maintained
between 2 and 3. In the following months ascites and
lower leg edema disappeared, the nutrition state
improved considerably, and finally the patient was
removed from the LT waiting list. While writing this
report the patient was well with a BMI of 21.
Conclusion
Serious NRH complicating HIV infection has been
recently reported by several groups [1-13]. Severe portal
hypertension with variceal bleedings and refractory
ascites can precipitate cachexia and threaten life of these
patients. So far HIV-related NRH portal hypertension
was treated symptomatically or referred for LT. Here we
show that clinical improvement of NRH with LMWH
therapy is possible. This case fits to the recent observa-
tions of Mallet et al. describing an HIV-associated oblit-
erative portal venopathy (HIV-OP) associated with a
thrombophilia. Ongoing thrombosis in the distal portal
veins in our patient is sustained by different observa-
tions: First, our patient presented with a low level of
protein S during the thrombophilia workup pointing to
a coagulation disorder that has been found in the major-
ity of patients presenting with NRH (protein S or C
deficiency and/or anti-cardiolipin antibodies) [10,14].
Second, the high D-dimer levels, low platelets and low
fibrinogen levels were suggestive of a constant thrombo-
tic process with activation of the coagulation system and
consumption of coagulation factors. Indeed, the fibrotic






Sept 2006 Nov 2006 Jan 2007 March 2007 April 2007 May 2007 June 2007 Jan 2009
Thrombocytes 133 105 139 75 189 353 351 339
D-Dimers - - - 7894 1107 425 242 -
Factor V 50 61 - 42 96 100 94 83
Total bilirubine 16 36 71 115 58 43 28 19
HIV viremia <4.0E+1 1.60E+03 <4.0E+1 <4.0E+1 - - - <4.0E+1
Absolut CD4 count 215 251 222 210 - - - 358
Figure 2 Evolution of liver function, clinical parameters and selected parameters of haemostasis were shown. Please note the changes
at the time of the switch from VKA to LMWH.
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placement of a TIPS did not correct impaired coagula-
tion balance. However, the introduction of a therapy
with LMWH (enoxaparin) was associated with clear-cut
biochemical and clinical improvement. Major recovery
of the general condition and absence of ascites paral-
leled the decrease of D-dimer, the increase of fibrinogen
and platelets. Indeed, LMWH seems to be superior to
VKA for the treatment of venous embolism as it has
been shown in patients with cancer [19]
Different hypotheses have been evoked as causes for
NRH in HIV-infected patients. Underlying diseases like
autoimmune disorders, malignancies or active viral infec-
tions such as HIV may create an imbalance of pro- and
anti-thrombotic factors. Rec e n t l y ,M a l l e te ta l .s h o w e d
that protein S levels are not only often low in patients
with HIV-associated NRH but the functionality of the
protein S is decreased due to increased levels of antipro-
tein S IgG. Their data suggest, that the antiprotein S IgG
were acquired during longstanding HIV infection and
contribute to the obliterative portal venopathy [10].
Although not vasculotropic, HIV exposes the vascular
endothelium constantly to viral stimuli such as viral pro-
teins upon lysis of infected CD4 T cells and viral-induced
pro-inflammatory cytokines. The latter increase the
endothelial cell permeability and facilitate monocyte
invasion and activation in the vessel wall [20]. Thus, HIV
directly alters the endothelium homeostasis and leads to
clotting dysfunction contributing to thrombotic compli-
cations in the arterial and venous system [21]. The direct
endothelial toxicity triggered by the virus has been
already evoked in patients with HIV-associated pulmon-
ary hypertension [22]. Moreover, there is clinical and in
vitro evidence that ART may have a toxic effect on the
endothelium and cause vascular dysfunction
[6,11,20,21,23]. Even if most cases of thromboembolic
events in HIV-infected have been associated with pro-
tease inhibitors, the nucleoside-reverse-transcriptase
inhibitor (NRTI) didanosin was associated in several stu-
dies with NCPH and NRH [2,12]. A recent case-control
study from the Swiss HIV cohort study showed that
among individual antiretroviral drugs, didanosin expo-
sure was a clear risk factor for development of NCPH
[12]. Indeed, didanosin is thought to lead to a mitochon-
drial damage in endothelial cells [24]. In any case, our
patient was treated with Didanosin for five years before
she developed symptoms of portal hypertension and
maybe the switch from didanosine to other ART compo-
nents has also contributed in the clinical improvement.
Taken together, this case underscores once again the
relation between thrombophilia and HIV-associated
NRH and emphasizes a potential beneficial role of antic-
oagulant therapy. A continuously activated prothrombo-
tic state was difficult to interrupt with VKA and only
after the introduction with LMWH the thrombotic mar-
kers ameliorated. Although potentially dangerous
because major bleedings can occur, we think that antic-
oagulant treatment with LMWH could play a role in the
prognosis in NRH as suggested by this case and may
avoid, at least in certain cases, liver transplantation.
However, this hypothesis should be evaluated in con-
trolled trial analyzing anticoagulant therapy with AVK
and LMWH.
Abbreviations
HIV: human immuno deficiency virus; NRH: nodular regenerative hyperplasia;
NCPH: noncirrhotic portal hypertension; HIV-OP: HIV-associated obliterative
portal venopathy; AVK: anti-vitamin K agent; LMWH: low-molecular-weight
heparin; TIPS: transjugular intrahepatic porto-systemic shunt; LT: liver
transplantation; AST: aspartate amino transferase; ALT: alanine amino
transferase; AP: alkaline phophatase; gGT: gamma glutamyl transpeptidase
Acknowledgements
Written consent was obtained from the patient for publication of this case
report.
Author details
1Department of Gastroenterology and Hepatology, University Hospitals of
Geneva, Rue Gabrielle-Perret-Gentil 4, Geneva 1211, Switzerland.
2Department of Hematology, Service of Angiology and Hemostasis,
University Hospitals of Geneva, Rue Gabrielle-Perret-Gentil 4, Geneva 1211,
Switzerland.
3Department of Pathology, University Hospitals of Geneva, Rue
Gabrielle-Perret-Gentil 4, Geneva 1211, Switzerland.
Authors’ contributions
FBi, FBo, LRB, AH and LS were directly involved in the clinical management
of the patient. FBi, FJ, collected the data and drafted the manuscript
together with FBo, AH and LS. LRB revised the manuscript critically and
added substantial intellectual content. All authors read and approved the
final manuscript.
Competing interests
There was no funding for this case report. All authors declare that they have
no conflict of interest in relation to this manuscript
Received: 6 July 2009
Accepted: 18 January 2010 Published: 18 January 2010
References
1. Reshamwala PA, Kleiner DE, Heller T: Nodular regenerative hyperplasia:
not all nodules are created equal. Hepatology 2006, 44:7-14.
2. Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H, Lascoux-
Combe C, Pol S: Nodular regenerative hyperplasia is a new cause of
chronic liver disease in HIV-infected patients. Aids 2007, 21:187-192.
3. Garvey LJ, Thomson EC, Lloyd J, Cooke GS, Goldin RD, Main J: Response to
Mallet et al., ‘Nodular regenerative hyperplasia is a new cause of chronic
liver disease in HIV-infected patients’. Aids 2007, 21:1494-1495.
4. Arey B, Markov M, Ravi J, Prevette E, Batts K, Nadir A: Nodular regenerative
hyperplasia of liver as a consequence of ART. Aids 2007, 21:1066-1068.
5. Sandrine PF, Sylvie A, Andre E, Abdoulaye D, Bernard L, Andre C: Nodular
regenerative hyperplasia: a new serious antiretroviral drugs side effect?.
Aids 2007, 21:1498-1499.
6. Maida I, Garcia-Gasco P, Sotgiu G, Rios MJ, Vispo ME, Martin-Carbonero L,
Barreiro P, et al: Antiretroviral-associated portal hypertension: a new
clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008,
13:103-107.
7. Maida I, Nunez M, Rios MJ, Martin-Carbonero L, Sotgiu G, Toro C, Rivas P,
et al: Severe liver disease associated with prolonged exposure to
antiretroviral drugs. J Acquir Immune Defic Syndr 2006, 42:177-182.
8. Saifee S, Joelson D, Braude J, Shrestha R, Johnson M, Sellers M,
Galambos MR, et al: Noncirrhotic portal hypertension in patients with
Bihl et al. BMC Gastroenterology 2010, 10:6
http://www.biomedcentral.com/1471-230X/10/6
Page 4 of 5human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol
2008, 6:1167-1169.
9. Tateo M, Sebagh M, Bralet MP, Teicher E, Azoulay D, Mallet V, Pol S, et al: A
new indication for liver transplantation: nodular regenerative
hyperplasia in human immunodeficiency virus-infected patients. Liver
Transpl 2008, 14:1194-1198.
10. Mallet VO, Varthaman A, Lasne D, Viard JP, Gouya H, Borgel D, Lacroix-
Desmazes S, et al: Acquired protein S deficiency leads to obliterative
portal venopathy and to compensatory nodular regenerative
hyperplasia in HIV-infected patients. Aids 2009, 23:1511-1518.
11. Chang PE, Miquel R, Blanco JL, Laguno M, Bruguera M, Abraldes JG,
Bosch J, et al: Idiopathic portal hypertension in patients with HIV
infection treated with highly active antiretroviral therapy. Am J
Gastroenterol 2009, 104:1707-1714.
12. Kovari H, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P, Calmy A, et al:
Association of noncirrhotic portal hypertension in HIV-infected persons
and antiretroviral therapy with didanosine: a nested case-control study.
Clin Infect Dis 2009, 49:626-635.
13. Schiano TD, Kotler DP, Ferran E, Fiel MI: Hepatoportal sclerosis as a cause
of noncirrhotic portal hypertension in patients with HIV. Am J
Gastroenterol 2007, 102:2536-2540.
14. Hillaire S, Bonte E, Denninger MH, Casadevall N, Cadranel JF, Lebrec D,
Valla D, et al: Idiopathic non-cirrhotic intrahepatic portal hypertension in
the West: a re-evaluation in 28 patients. Gut 2002, 51:275-280.
15. Al-Mukhaizeem KA, Rosenberg A, Sherker AH: Nodular regenerative
hyperplasia of the liver: an under-recognized cause of portal
hypertension in hematological disorders. Am J Hematol 2004, 75:225-230.
16. Gonzalez-Alegre MT, Guerra-Vales JM, Martinez G, Gutierrez A, Guillen V:
Nodular regenerative hyperplasia of the liver and Hodgkin’s disease: a
case report. Acta Gastroenterol Belg 2004, 67:358-360.
17. Dumortier J, Bizollon T, Scoazec JY, Chevallier M, Bancel B, Berger F,
Ducerf C, et al: Orthotopic liver transplantation for idiopathic portal
hypertension: indications and outcome. Scand J Gastroenterol 2001,
36:417-422.
18. Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC: Liver
transplantation for severe intrahepatic noncirrhotic portal hypertension.
Liver Transpl 2005, 11:627-634, discussion 610-621.
19. Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schunemann HJ:
Low-molecular-weight heparins are superior to vitamin K antagonists for
the long term treatment of venous thromboembolism in patients with
cancer: a cochrane systematic review. J Exp Clin Cancer Res 2008, 27:21.
20. Kline ER, Sutliff RL: The roles of HIV-1 proteins and antiretroviral drug
therapy in HIV-1-associated endothelial dysfunction. J Investig Med 2008,
56:752-769.
21. Jacobson MC, Dezube BJ, Aboulafia DM: Thrombotic complications in
patients infected with HIV in the era of highly active antiretroviral
therapy: a case series. Clin Infect Dis 2004, 39:1214-1222.
22. Recusani F, Di Matteo A, Gambarin F, D’Armini A, Klersy C, Campana C:
Clinical and therapeutical follow-up of HIV-associated pulmonary
hypertension: prospective study of 10 patients. Aids 2003, 17(Suppl 1):
S88-95.
23. Klein SK, Slim EJ, de Kruif MD, Keller TT, ten Cate H, van Gorp EC,
Brandjes DP: Is chronic HIV infection associated with venous thrombotic
disease? A systematic review. Neth J Med 2005, 63:129-136.
24. Walker UA, Setzer B, Venhoff N: Increased long-term mitochondrial
toxicity in combinations of nucleoside analogue reverse-transcriptase
inhibitors. Aids 2002, 16:2165-2173.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.
biomedcentral.com/1471-230X/10/6/prepub
doi:10.1186/1471-230X-10-6
Cite this article as: Bihl et al.: Anticoagulant therapy for nodular
regenerative hyperplasia in a HIV-infected patient. BMC Gastroenterology
2010 10:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bihl et al. BMC Gastroenterology 2010, 10:6
http://www.biomedcentral.com/1471-230X/10/6
Page 5 of 5